Eviplera® as a switch option for HIV infected patients—Review of GS-US-264-106 (SPIRIT) and GS-US-264-0111 studies

Publication date: Available online 6 August 2014 Source:HIV & AIDS Review Author(s): Kamila Wójcik The purpose of this paper is to present the safety and efficacy of Eviplera® in HIV-infected naïve- and treatment-experienced patients. This paper is the review of ECHO/THRIVE studies comparing rilpivirine with efavirenz in treatment-naïve patients and GS-US-264-106 (SPIRIT)/GS-US-264-0111 studies showing efficacy of switching to Eviplera® in virologically suppressed HIV-infected patients. Based on results obtained from these studies, Eviplera® is indicated not only for HIV-infected treatment-naïve patients with baseline viral load less than 100000copies/mL but it is also a switching option in patients who have achieved virologic control on another regimen. Eviplera® (RPV/FTC/TDF) has demonstrated non-inferior efficacy but better tolerability than other antiretroviral drugs and may be a switching option in patients experienced side effects from previous regimen or in those who wish to simplify antiretroviral therapy.
Source: HIV and AIDS Review - Category: Infectious Diseases Source Type: research